Novel SGLT2 inhibitor: first‐in‐man studies of antisense compound is associated with unexpected renal effects

The antisense compound ISIS 388626 selectively inhibits renal glucose reabsorption by inhibiting the sodium–glucose cotransporter‐2 (SGLT2) mRNA expression. It is developed as an insulin‐independent treatment approach for type 2 diabetes mellitus (T2DM). The safety, tolerability, pharmacokinetics, a...

Descripción completa

Detalles Bibliográficos
Autores principales: van Meer, Leonie, van Dongen, Marloes, Moerland, Matthijs, de Kam, Marieke, Cohen, Adam, Burggraaf, Jacobus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461644/
https://www.ncbi.nlm.nih.gov/pubmed/28596840
http://dx.doi.org/10.1002/prp2.292

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461644/
https://www.ncbi.nlm.nih.gov/pubmed/28596840
http://dx.doi.org/10.1002/prp2.292

Ejemplares similares